Eli Lilly and the FDA approved an experimental obesity drug (retatrutide) for one anonymous 79-year-old through a compassionate use program, according to reporting from STAT News and confirmed by multiple outlets including BBC and Forbes. The patient's identity remains unknown, though the timing and age have prompted speculation about whether the patient is President Trump — a claim the White House has explicitly denied. What matters: compassionate use programs are legitimate emergency pathways for experimental drugs, but the secrecy around a high-profile patient raises questions about potential conflicts of interest or preferential access based on political connections.